Literature DB >> 18781468

Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease.

Mariano J Levin1, Johan Hoebeke.   

Abstract

Anti-beta(1)-adrenoceptor autoantibodies, first described in sera of patients with Chagas' disease, are now well documented in patients with idiopathic dilated cardiomyopathy. The following review summarizes the knowledge we have about the structural basis of receptor-antibody interactions, about their mechanisms of action and about their pathogenicity. While the origin of anti-receptor antibodies with agonist-like activity in Chagas' disease might be ascribed to recognition by anti-parasite antibodies of an epitope, localized on the second extracellular loop of the beta(1)-adrenoceptor, the origin of such antibodies in idiopathic dilated cardiomyopathy remains unknown. The hypothesis of a similar origin for anti-receptor antibodies in both diseases is forwarded.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781468     DOI: 10.1080/08916930802031702

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  9 in total

Review 1.  The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease.

Authors:  Udi Nussinovitch; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 2.  Chronic Chagas' heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine.

Authors:  Silvia Gilka Muñoz-Saravia; Annekathrin Haberland; Gerd Wallukat; Ingolf Schimke
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

Review 3.  Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.

Authors:  V Balouz; F Agüero; C A Buscaglia
Journal:  Adv Parasitol       Date:  2016-11-14       Impact factor: 3.870

Review 4.  Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy.

Authors:  Priyesh A Patel; Adrian F Hernandez
Journal:  Eur J Heart Fail       Date:  2013-05-02       Impact factor: 15.534

Review 5.  Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function.

Authors:  L R Herda; S B Felix; F Boege
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 6.  Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy.

Authors:  Lifang Zhao; Zhaoying Fu
Journal:  J Immunol Res       Date:  2018-05-07       Impact factor: 4.818

7.  Prognostic Value of β1 Adrenergic Receptor Autoantibody and Soluble Suppression of Tumorigenicity-2 in Patients With Acutely Decompensated Heart Failure.

Authors:  Yanxiang Sun; Li Feng; Bing Hu; Jianting Dong; Liting Zhang; Xuansheng Huang; Yong Yuan
Journal:  Front Cardiovasc Med       Date:  2022-02-10

8.  Anti-Trypanosoma cruzi cross-reactive antibodies detected at high rate in non-exposed individuals living in non-endemic regions: seroprevalence and association to other viral serologies.

Authors:  Esber S Saba; Lucie Gueyffier; Marie-Laure Dichtel-Danjoy; Bruno Pozzetto; Thomas Bourlet; François Gueyffier; Yahia Mekki; Hans Pottel; Ester C Sabino; Philippe Vanhems; Maan A Zrein
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

Review 9.  Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature.

Authors:  Navkaranbir S Bajaj; Kartik Gupta; Nitin Gharpure; Mike Pate; Lakshay Chopra; Rajat Kalra; Sumanth D Prabhu
Journal:  ESC Heart Fail       Date:  2020-03-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.